As such, anti-VEGF therapies have been studied in animal models of both type 1 and type 2 diabetes with some success observed; for example, decreased albuminuria and reduced glomerular hypertrophy have been observed [30,53,54]. The gene discussed is VEGFA; the disease is type 2 diabetes mellitus.